MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02814cam a2200241 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
9780128035993 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220107t2016 xxu||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780128035993 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
012803582X |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kelley, Mark Richard |
| 245 #0 - TITLE STATEMENT |
|---|
| Title |
DNA repair in cancer therapy: molecular targets and clinical applications |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
2nd ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
London : |
| Name of publisher, distributor, etc. |
Academic Press, |
| Date of publication, distribution, etc. |
2016 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (xix, 444 pages):color illustrations |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
1. Overview of Current Targets and Clinical Trials: Bench to Clinic 2. MGMT a Critical DNA Repair Gene Target for Chemotherapy Resistance 3. Blockade of Base Excision Repair: Inhibition of Small Lesions Results in Big Consequences to Cancer Cells 4. PARP Inhibitors -- Scientific Rationale and Clinical Development for Cancer 5. Inhibiting Selective DNA Polymerases for Therapeutic Intervention 6. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications 7. Homologous Recombination and ATM/ATR Targets 8. DNA Double Strand Break Repair by Nonhomologous End Joining and its Clinical Relevance 9. Mismatch repair 10. DNA Repair Signaling Targets 11. Personalized Cancer Medicine: DNA Repair Alterations is a Promising Predictive Marker in Cancer 12. The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies 13. Radiation DNA damage and use in cancer/therapeutics/dna repair 14. Fanconi Anemia- cross-link repair 15. Translesion DNA polymerases 16. BRCA1-BRCA2 pathway for HR and synthetic lethality 17. Synthetic lethality 18. Mechanisms of Resistance to Clinical PARP Inhibitors |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
DNA Repair and Cancer Therapy: Molecular Targets and Clinical Applications, Second Edition provides a comprehensive and timely reference that focuses on the translational and clinical use of DNA repair as a target area for the development of diagnostic biomarkers and the enhancement of cancer treatment. Experts on DNA repair proteins from all areas of cancer biology research take readers from bench research to new therapeutic approaches. This book provides a detailed discussion of combination therapies, in other words, how the inhibition of repair pathways can be coupled with chemotherapy, radiation, or DNA damaging drugs. Newer areas in this edition include the role of DNA repair in chemotherapy induced peripheral neuropathy, radiation DNA damage, Fanconi anemia cross-link repair, translesion DNA polymerases, BRCA1-BRCA2 pathway for HR and synthetic lethality, and mechanisms of resistance to clinical PARP inhibitors. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) |
|---|
| Topical term or geographic name as entry element |
Cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) |
|---|
| Topical term or geographic name as entry element |
DNA repair. |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Fishel, Melissa L. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://go.openathens.net/redirector/nhs?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20150002404">https://go.openathens.net/redirector/nhs?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20150002404</a> |